Abstract
Fas molecule is one of the main important molecules involved in apoptotic cell death. Single nucleotide polymorphisms in the promoter of Fas gene at positions −1377G/A and −670 A/G may affect its expression and play an important role in the pathology of leukemia. In the present study the association between these polymorphisms and risk of the development of acute lymphoblastic leukemia (ALL) in children with ALL compared to cancer-free control subjects was examined by polymerase chain reaction- based restriction fragment length polymorphism. The relationship between the polymorphisms and clinical and laboratory features of the patients and response to therapy were determined. No significant differences in genotype and allele frequencies between the patients and the control subjects at positions −670 and −1377 were detected. Evaluation of the prognostic factors revealed an association between the GG genotype at position −670 and liver involvement in ALL patients (p < 0.04). Although patients with −1377 AA genotype showed shorter mean complete remission duration, the result of survival analysis did not reach to be significant. In conclusion, results of this study showed no contribution of Fas genotypes at positions −670 and −1377 to risk of ALL in children. The association of Fas GG genotype at position −670 with liver involvement in the patients may show its important role in prognosis of ALL.
Similar content being viewed by others
References
Daneshbod Y, Amirghofran Z, Tabei SZ (2005) Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 52:109–114
Amirghofran Z, Monabati A, Gholijani N (2004) Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res 10:37–41
Kaufmann T, Strasser A, Jost PJ (2012) Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19:42–50
Lavrik IN, Krammer PH (2012) Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 19:36–41
Itoh N, Yonehara S (2000) The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66:233–243
Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14:821–822
Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1 gene. Eur J Immunol 24:3057–3062
Muschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325
Sibley K, Rollinson S, Allan JM et al (2003) Functional Fas promoter polymorphism are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330
Wu J, Siddiqui J, Nihal M, Vonderheid EC et al (2011) Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 15:185–191
Zhang Z, Xue H, Gong W et al (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30:487–493
Lei D, Sturgis EM, Wang LE et al (2010) FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 19:1484–1491
Cao Y, Miao XP, Huang MY et al (2010) Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49:944–950
Shao P, Ding Q, Qin C et al (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71:1122–1130
Zhang W, Li C, Wang J, He C (2012) Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59:141–146
Zhang X, Miao X, Sun T et al (2005) Functional polymorphisms in cell death pathway genes Fas and FasL contribute to risk of lung cancer. J Med Genet 42:479–484
Scholl V, Stefanoff CG, Hassan R et al (2007) Spector N, Renault IZ. Mutations within the 5′ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma 48:957–963
Peter AM, Kohfink B, Martin H et al (1999) Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin’s disease. Exp Hematol 27:868–874
Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266–4270
Farre L, Bittencourt AL, Silva-Santos G et al (2008) Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83:220–222
Nair RR, Khanna A, Singh K (2012) Association of FAS −1377 G > A and FAS −670 A > G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk. J Reprod Immunol 93:114–118
Zhao XF, Reitz M, Chen QC, Stass S (2011) Pathogenesis of early leukemia and lymphoma. Cancer Biomark 9:341–374
Traver D, Akashi K, Weissman IL, Lagasse E (1998) Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9:47–57
Chávez-Galán L, Arenas-Del Angel MC, Zenteno E et al (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6:15–25
Arasteh JM, Sarvestani EK, Aflaki E, Amirghofran Z (2010) Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. Immunol Investig 39:27–38
Villa-Morales M, Fernández-Piqueras J (2012) Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 16:85–101
Rozenfeld-Granot G, Toren A, Amariglio N (2001) Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp Hematol 29:228–233
Beltinger C, Kurz E, Böhler T (1998) CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 15:3943–3951
Beltinger C, Böhler T, Karawajew L et al (1998) Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 102:722–728
Kim HJ, Jin XM, Kim HN et al (2010) Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 29:619
Mehta PA, Gerbing RB, Alonzo TA et al (2008) FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children’s oncology group report. Clin Cancer Res 1:7896–7899
Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M (2011) The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia. Arch Iran Med 14:170–174
Amirghofran Z, Daneshbod Y, Gholijani N (2009) Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res 17:447–454
Fathi M, Amirghofran Z, Shahriari M (2012) Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol 29:2046–2052
Sunter NJ, Scott K, Hills R et al (2012) A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 5:196–205
Acknowledgments
The present article was supported by grant no. 90-01-3551 from Shiraz University of Medical Sciences.
Conflicts of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valibeigi, B., Amirghofran, Z., Golmoghaddam, H. et al. Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis. Pathol. Oncol. Res. 20, 367–374 (2014). https://doi.org/10.1007/s12253-013-9705-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-013-9705-2